Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 1.07%, ranking 26th among 31 primary industries, outperforming the CSI 300 index which fell by 1.19% [4][15] - The valuation of the pharmaceutical and biotechnology industry as of January 23, 2026, is a PE (TTM overall method, excluding negative values) of 30.31x, down from 30.56x in the previous period, indicating a decline in valuation below the average [4][19] - The top three sub-industries by PE (TTM overall method, excluding negative values) are vaccines (47.34x), hospitals (44.94x), and other medical services (40.38x), while the lowest valuation is in pharmaceutical circulation (15.31x) [4][19] - During the reporting period, 34 listed companies in the pharmaceutical and biotechnology sector saw a net reduction in shareholder holdings amounting to 2.125 billion yuan, with 2 companies increasing holdings by 63 million yuan and 32 companies reducing holdings by 2.189 billion yuan [4] Industry Trends - The 2026 JPM Conference highlighted Chinese innovative drugs as a global focus, with several Chinese companies showcasing advancements in PD-1/VEGF bispecific antibodies, ADCs, and cell therapies [7] - The report suggests focusing on innovative pharmaceutical companies with differentiated pipelines that have received validation through high-quality collaborations with multinational pharmaceutical companies, particularly in key areas such as ADCs, bispecific antibodies, and siRNA therapies [7] Important Industry News - The Ministry of Commerce and eight other departments issued opinions on promoting high-quality development in the drug retail industry, projecting a growth in the drug circulation market from 2.41 trillion yuan in 2020 to 2.95 trillion yuan by 2024, a 22.4% increase [24] - The National Healthcare Security Administration released guidelines for pricing projects related to surgical and treatment auxiliary operations, aiming to standardize and promote the use of advanced medical technologies [27][28] - Notable approvals include Daiichi Sankyo's "Trastuzumab Deruxtecan" for advanced HER2-positive gastric cancer, and AbbVie’s "Risankizumab" for ulcerative colitis, showcasing significant advancements in treatment options [38][44]

Core Viewpoint - The article discusses the investment framework for the pharmaceutical industry ETF in 2026, emphasizing a dual-driven approach of demand and innovation to navigate the market recovery and differentiation after a prolonged bear market since 2021 [29]. Market Review - The CITIC Pharmaceutical Index decreased by 0.38%, outperforming the CSI 300 Index by 0.24 percentage points, ranking 25th among 30 primary industries [9]. - The top ten stocks by increase this week included ST Changyao, Hualan Biological Engineering, and Kangzhong Medical, with gains ranging from 6% to 70.38% [9]. - The bottom ten stocks by decrease included Kain Technology and Aidi Pharmaceutical, with declines of up to 45% [9]. Industry and Stock Events - The article highlights a shift in funding from active to passive management in the pharmaceutical sector, with passive funds becoming a significant part of the long-term funding structure [18]. - The article notes that the innovation drug sector is expected to see a transition from quantity to quality, focusing on differentiated products and internationalization by 2025 [12]. - The medical device sector is experiencing a recovery in bidding volumes, particularly in imaging equipment, and is benefiting from policies promoting home medical devices and accelerated overseas expansion [12]. - The article discusses the favorable conditions for the blood products industry, with relaxed approval for plasma stations and a clear growth path for the industry during the 14th Five-Year Plan period [13]. Investment Strategy - The article proposes a dynamic ETF configuration framework for the pharmaceutical sector, categorized into three layers: a core base of broad-based ETFs, a dual-driven layer focusing on innovative drugs and medical devices, and a defensive layer using traditional Chinese medicine and overseas biotech [22]. - The article emphasizes the importance of a systematic approach to ETF selection, considering liquidity, tracking quality, and cost [24]. - It suggests that the pharmaceutical sector is entering a new growth cycle driven by rigid demand and continuous innovation, necessitating a more structured and rhythmic ETF combination strategy [22].

医药 医药 2026 年 01 月 22 日 行业日报 看好/维持 太平洋医药日报（20260122）：第一三共 ADC 新药 R-DXd 在华获 突破性疗法认定 ◼ 走势比较 (10%) 0% 10% 20% 30% 40% 25/1/22 25/4/5 25/6/17 25/8/29 25/11/10 26/1/22 ◼ 子行业评级 | 化学制药 | 无评级 | | --- | --- | | 中药生产 | 无评级 | | 生物医药Ⅱ | 中性 | | 其 他 医 药 医 | 中性 | | 疗 | | 相关研究报告 <<太平洋医药日报（20260121）：礼来 ADC 药物 LY4170156 获 FDA 突破性疗 法认定>>--2026-01-22 <<太平洋医药日报（20260120）：GSK 将以 22 亿美金收购 RAPT>>--2026- 01-21 <<太平洋医药日报（20260119）：武田 Oveporexton 在 华 申 报 上 市 >>-- 2026-01-20 证券分析师：周豫 电话： E-MAIL：zhouyua@tpyzq.com 分析师登记编号：S1190523060002 ...

Core Viewpoint - The approval of trastuzumab deruxtecan for a new indication in China marks a significant milestone for Daiichi Sankyo and AstraZeneca, expanding its use in treating HER2-positive gastric cancer patients [1] Group 1: Drug Approval and Indication - Trastuzumab deruxtecan has received approval from the National Medical Products Administration of China for use in adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have previously received a treatment regimen containing trastuzumab [1] - This new indication is the sixth approved use of trastuzumab deruxtecan in China and the second indication related to HER2-positive gastric cancer [1] Group 2: Clinical Trial Results - The approval is based on results from the international, multicenter, randomized, open-label phase 3 study DESTINY-Gastric04, which demonstrated statistically significant and clinically meaningful improvements in overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) [1] - The safety profile of trastuzumab deruxtecan was found to be acceptable and manageable, consistent with known safety characteristics, with no new safety issues identified [1] - Results from the DESTINY-Gastric04 study were presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting and published in the New England Journal of Medicine [1]

Core Insights - Shanghai's GDP reached 56,708.71 billion yuan in 2025, with a year-on-year growth of 5.4%, surpassing the national average and ranking fifth globally among cities [1] - The city has shown resilience in economic growth despite external challenges, with a focus on structural transformation and new driving forces [2][3] Economic Structure and Growth - Shanghai's economic structure is undergoing significant changes, with emerging industries like integrated circuits, biomedicine, and artificial intelligence leading the way, achieving a combined output exceeding 2 trillion yuan and a growth rate of 9.6% [2] - The manufacturing output of integrated circuits and AI grew by 15.1% and 13.6%, respectively, indicating a shift towards innovation-driven growth [2] Industrial Performance - Strategic emerging industries in Shanghai saw a 6.5% increase in total output, accounting for 45% of the total industrial output, with notable growth in new energy and high-end equipment sectors [3] - Traditional growth models are transitioning to innovation and efficiency-driven approaches, enhancing overall economic quality and structure [3] Consumer Market Dynamics - Shanghai's retail sales of consumer goods grew by 4.6% in 2025, with various innovative consumption events boosting market activity [4] - The city's policy to promote the replacement of old consumer goods led to over 120 billion yuan in sales, benefiting more than 21.95 million people [4] Employment and Income Growth - The per capita disposable income in Shanghai reached 91,987 yuan, reflecting a 4.1% increase, which supports consumer spending [4] - The city's inbound tourism saw a historic high of 9.36 million visitors, a 40% increase from the previous year, contributing to the local economy [5] Business Environment and Financial Sector - Shanghai implemented measures to reduce business burdens, expected to save over 100 billion yuan for enterprises in 2025 [5] - The number of licensed financial institutions in Shanghai reached 1,813, with significant growth in financial market transactions, totaling 40,589.5 billion yuan, a 11.2% increase [6] International Trade and Shipping - Shanghai's foreign trade volume reached 4.51 trillion yuan, marking a 5.6% increase, with exports growing by 10.8% [6] - The port's container throughput reached 55.06 million TEUs, a 6.9% increase, maintaining its position as the world's busiest port [6] Innovation and Technology - The total value of technology contracts in Shanghai reached 649.68 billion yuan, a 24.9% increase, indicating a strong innovation ecosystem [7] - The city aims to leverage its "five centers" strategy to enhance its global competitiveness and drive technological advancements [7]

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. is recognized as a leading player in China's biopharmaceutical industry, transitioning from generic drugs to innovative drugs, with its strategic movements indicating the development direction of the entire Chinese pharmaceutical industry [1] Group 1: Strategic Overview - Hengrui has undergone a painful transformation over the past five years, successfully navigating the challenges posed by the National Drug Centralized Procurement (VBP), with 2023 revenue reaching 22.82 billion yuan, a year-on-year increase of 7.26%, and net profit of 4.30 billion yuan, up 10.14% [2] - The company is expected to accelerate growth in 2024 and 2025, with projected revenue of 27.99 billion yuan in 2024, a significant year-on-year increase of 22.63%, and innovative drug revenue surpassing 60% by mid-2025 [2] Group 2: Investment Logic Reconstruction - The core investment logic for Hengrui is restructured around four dimensions: the clearance of existing risks and realization of innovation, global competitiveness of the ADC platform, explosive potential of chronic disease pipelines, and iterative internationalization models [4] - The ADC pipeline, led by SHR-A1811, has established a competitive edge against imported drugs and validated its underlying technology platform (HRMAP) through extensive external licensing [4] Group 3: Financial Deep Dive - Hengrui's financial reports show a clear V-shaped recovery trend, with 2023 revenue of 22.82 billion yuan and innovative drug revenue reaching 10.64 billion yuan, a year-on-year increase of 22.1% [6] - By 2025, the company anticipates revenue of 33.65 billion yuan, with net profit projected between 6 to 7 billion yuan, reflecting a growth rate of approximately 29% [6] - Operating cash flow surged by 504.12% to 7.644 billion yuan in 2023, indicating strong cash generation capabilities [10] Group 4: Oncology Pipeline Insights - Hengrui's oncology pipeline has shifted from a "Me-too/Me-better" strategy to a "Best-in-Class" and "First-in-Class" approach, with the ADC platform becoming a new cornerstone [12] - SHR-A1811 is positioned as a strategic asset, directly competing with DS-8201, and has received breakthrough therapy designations for multiple indications [14] Group 5: Non-Oncology Growth Areas - Hengrui's deep layout in non-oncology fields serves as a stabilizer for its performance and a second growth curve, particularly in metabolic diseases, cardiovascular, and autoimmune areas [23] - The company is actively participating in the GLP-1 market, with HRS9531 showing potential for superior efficacy in weight loss and diabetes management [24] Group 6: Globalization Strategy 2.0 - Hengrui's internationalization strategy has evolved from simple export to a more integrated approach involving NewCo and licensing-out models, allowing for risk isolation and capital leverage [33] - The NewCo model enables Hengrui to finance high-risk clinical developments through partnerships with top-tier venture capital, mitigating cash flow strain [34] Group 7: Policy Environment and Market Access - The impact of the VBP has diminished, with Hengrui's main generic products now serving as cash cows to support innovative drug development [41] - Successful negotiations in the National Reimbursement Drug List (NRDL) for innovative drugs are expected to catalyze growth, despite average price reductions of around 60% [42]

Core Viewpoint - Merck (MRK.US) is actively seeking large-scale acquisitions, with CEO Rob Davis indicating the company sees "multiple opportunities" for significant deals worth hundreds of billions of dollars, particularly before the patent expiration of its blockbuster drug, Keytruda [1][2] Group 1: Acquisition Strategy - Merck is preparing for the impact of patent expirations, with analysts predicting a potential sales erosion of $18 billion over the next five years due to the expiration of Keytruda's patent in 2028 [2][3] - The company has already completed several large transactions in the past 18 months, including the acquisition of Verona Pharma for approximately $10 billion and Cidara for about $9.2 billion, demonstrating its commitment to expanding its product portfolio [4] Group 2: Focus Areas for Future Acquisitions - Oncology remains the top priority for Merck, with plans to diversify its cancer product line beyond Keytruda, including potential acquisitions in the range of $28 billion to $32 billion for companies like Revolution Medicines, which focuses on RAS pathway-targeted therapies [5][6] - The company is also interested in antibody-drug conjugates (ADCs) and next-generation tumor payload platforms, reflecting a strategic bet on ADCs as a growth engine post-Keytruda [5][6] - New immunotherapy modalities, such as T-cell engagers, are likely to attract Merck's interest, as evidenced by its acquisition of Harpoon Therapeutics to enhance its oncology pipeline [6][7] Group 3: Broader Strategic Goals - Merck has raised its long-term sales target for its cardiovascular and respiratory business to approximately $20 billion, indicating a strategic shift towards these areas [7] - The company is likely to pursue differentiated small molecules or biologics for chronic diseases like COPD and asthma, as well as assets in cardiovascular metabolism that can achieve significant sales by 2028-2032 [7]

Core Insights - The article highlights the rapid growth and international recognition of the company, Yingen Biotech, which specializes in ADC (Antibody-Drug Conjugate) drug development since its establishment in 2019 [1] Group 1: Company Overview - Yingen Biotech has developed four leading technology platforms in the ADC field: DITAC (Immunotoxin Antibody Conjugate), DIBAC (Innovative Bispecific Antibody Conjugate), DIMAC (Immunomodulatory Antibody Conjugate), and DUPAC (Unique Payload Antibody Conjugate) [1] - The company has established a competitive ADC pipeline targeting various promising cancer markers, including HER2, B7-H3, HER3, TROP2, and B7-H4, as well as self-immune targets like BDCA2 [1] - Despite being a relatively new company, Yingen Biotech has secured licensing and strategic partnerships with well-known pharmaceutical companies, including BioNTech and GlaxoSmithKline, for several of its ADC pipelines [1] Group 2: Product Highlights - DB-1311 (B7-H3 ADC) shows significant potential in treating various cancers, particularly prostate cancer, and is closely following the clinical progress of Ifinatamab deruxtecan, which is currently in Phase III trials [2] - DB-1303 (HER2 ADC) aims to differentiate itself in the market by targeting both endometrial cancer (EC) and breast cancer (BC), with the potential to become the first HER2 ADC used for both high and low expression EC [2] - The global market for DB-1303 is promising, especially as it is one of the few ADCs progressing to Phase III clinical trials for HER2-Low BC, alongside DS-8201 [2] Group 3: Strategic Collaborations - Yingen Biotech has formed a strategic partnership with BioNTech, positioning itself within the emerging "second-generation IO+ADC" cancer treatment landscape, which is attracting interest from major multinational corporations [3] - The collaboration with BioNTech, which has also partnered with Bristol-Myers Squibb, enhances Yingen Biotech's global clinical development and commercialization capabilities, maximizing the potential value of its ADC pipeline [3]

Investment Rating - The investment rating for the company is "Buy" [11] Core Insights - The "second-generation IO+ADC" is expected to become the next trend in cancer treatment, attracting multiple multinational corporations (MNCs) such as Merck, BMS, BioNTech, AstraZeneca, and Pfizer. In this new global competition, the company has distinguished itself with strong innovation capabilities and a rapidly advancing pipeline, having formed a deep partnership with BioNTech, which has also established a strategic collaboration with BMS. This collaboration is expected to maximize the global value of the company's ADC pipeline [3][9]. Summary by Sections Company Overview - The company, established in 2019, focuses on the development of ADC drugs and has built four leading technology platforms: DITAC (Duality Immune Toxin Antibody Conjugate), DIBAC (Duality Innovative Bispecific Antibody Conjugate), DIMAC (Duality Immune Modulating Antibody Conjugate), and DUPAC (Duality Unique Payload Antibody Conjugate). It has developed a competitive ADC pipeline targeting various promising cancer antigens [6][26]. ADC Pipeline and Collaborations - The company has multiple ADC pipelines that have gained recognition and partnerships with well-known pharmaceutical companies. Notably, DB-1303 (HER2 ADC), DB-1311 (B7-H3 ADC), and DB-1305 (TROP2 ADC) have been licensed to BioNTech, while DB-1324 (CDH17 ADC) has been licensed to GlaxoSmithKline, and DB-1312 (B7-H4 ADC) has been licensed to BeiGene [6][29]. Specific Drug Insights - DB-1311 (B7-H3 ADC) shows significant potential across various cancers, with promising efficacy and safety profiles, particularly in prostate cancer, where it is positioned as a global best-in-class candidate. The drug is currently in advanced clinical stages [7][35]. - DB-1303 (HER2 ADC) is advancing in the U.S. and aims to differentiate itself in the uterine cancer market, with potential sales exceeding $5 billion by 2025. It is the only HER2 ADC in advanced clinical stages besides DS-8201 [8][9]. - The company has established a strong foothold in the ADC market, with a focus on global clinical trials and strategic collaborations, positioning itself as a potential international biopharma leader [6][29].

Group 1 - The Hong Kong innovation drug sector has recorded a three-day consecutive rise since the beginning of 2026, with a rebound of approximately 10% in the main innovation drug index [1][8] - The Hong Kong Innovation Drug ETF (520880) has accumulated a gain of 9.24% since the start of the year, with a notable increase of over 3.4% on January 7 [1][8] - In 2025, the innovation drug sector represented by Hong Kong stocks saw an overall increase of over 60%, becoming a significant player in the market [3][11] Group 2 - The surge in the innovation drug sector at the beginning of 2025 is attributed to multiple catalysts, including favorable policies, better-than-expected industry data, and the approach of important industry conferences [5][13] - Significant developments include the approval of the first domestically produced CTLA-4 inhibitor "Daboshu" by Innovent Biologics and the approval of TROP2 ADC "Dercutuzumab" for breast cancer by AstraZeneca and Daiichi Sankyo, enhancing the ADC sector's competitive edge [5][13] - The total amount of outbound licensing for Chinese innovative drugs reached $135.655 billion in 2025, with 157 transactions, both setting historical records [5][13] Group 3 - The sector's valuation is currently at a relatively low level following previous adjustments, and there has been a noticeable inflow of funds driven by strong fundamental data [6][14] - Investment outlook for 2026 focuses on innovation and international expansion, with an emphasis on companies that have achieved significant business development (BD) transactions and those with unexpected overseas clinical progress [6][14] - The industry is entering a "dual-driven" 3.0 era of product development and commercial sales, with a clear upward trend in demand for next-generation therapies such as ADCs and dual antibodies [6][14] Group 4 - New technologies such as AI in drug development and brain-computer interfaces are expected to accelerate industrialization due to supportive policies and pricing [7][15] - Areas facing potential recovery include medical device exports, consumer healthcare, and OTC traditional Chinese medicine, which may present wave-like investment opportunities under improving policies or macroeconomic conditions [7][15] - The investment logic in the pharmaceutical sector for 2026 has shifted from broad-based gains to selective alpha strategies, favoring companies with robust technology and clear commercialization paths [7][15]